申请人:Glaxo Group Limited
公开号:US08207176B2
公开(公告)日:2012-06-26
The present invention is directed to novel substituted 2,4,8-trisubstituted 8H-pyrido[2,3-d]pyrimidin-7-one containing compounds, compositions, and use in therapy as CSBP/RK/p38 kinase inhibitors of Formulas (V) and (Va)
wherein inter alia,
G5 and G6 are nitrogen and CH, provided that only one of G5 or G6 is nitrogen and the other is CH;
R1 is C(Z)N(R10′)(CR10R20)vRb, C(Z)O(CR10R20)vRb, N(R10′)C(Z)(CR10R20)vRb, N(R10′)C(Z)N(R10′)(CR10R20)vRb, or N(R10′)OC(Z)(CR10R20)vRb;
R1′ is independently selected at each occurrence from halogen, C1-4 alkyl, halo-substituted-C1-4 alkyl, cyano, nitro, (CR10R20)v′NRdRd′, (CR10R20)v′C(O)R12, SR5, S(O)R5, S(O)2R5, or (CR10R20)v′OR13;
Rb is hydrogen, C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic, or heterocyclylC1-10 alkyl moiety, which moieties, excluding hydrogen, may all be optionally substituted;
X is R2, OR2′, S(O)mR2′, (CH2)n′N(R10′)S(O)mR2′, (CH2)n′N(R10′)C(O)R2′, (CH2)n′NR4R14, (CH2)n′N(R2′)(R2″), or N(R10′)RhNH—C(═N—CN)NRqRq′; and
R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted.
本发明涉及一种新型的取代的2,4,8-三取代8H-吡啶[2,3-d]嘧啶-7-酮化合物、组合物和在治疗中用作CSBP/RK/p38激酶抑制剂的化合物,其化学式为(V)和(Va),其中,G5和G6是氮和CH,但只有G5或G6是氮,另一个是CH;R1是C(Z)N(R10′)(CR10R20)vRb,C(Z)O(CR10R20)vRb,N(R10′)C(Z)(CR10R20)vRb,N(R10′)C(Z)N(R10′)(CR10R20)vRb或N(R10′)OC(Z)(CR10R20)vRb;R1′在每次出现时独立选择自卤素、C1-4烷基、卤代C1-4烷基、氰基、硝基、(CR10R20)v′NRdRd′、(CR10R20)v′C(O)R12、SR5、S(O)R5、S(O)2R5或(CR10R20)v′OR13;Rb是氢、C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂芳基、杂芳基C1-10烷基、杂环或杂环基C1-10烷基基团,这些基团(不包括氢)都可以选择性地被取代;X是R2、OR2′、S(O)mR2′、(CH2)n′N(R10′)S(O)mR2′、(CH2)n′N(R10′)C(O)R2′、(CH2)n′NR4R14、(CH2)n′N(R2′)(R2″)或N(R10′)RhNH—C(═N—CN)NRqRq′;而R3是C1-10烷基、C3-7环烷基、C3-7环烷基C1-10烷基、芳基、芳基C1-10烷基、杂芳基、杂芳基C1-10烷基、杂环或杂环基C1-10烷基基团,这些基团都可以选择性地被取代。